The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when ...

Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial ...

Anticipated late-stage results in the skin disease hidradenitis suppurativa were described by analysts as “disappointing” and ...

Learn how softgels have helped sponsors across the industry improve the efficacy and stability of their therapeutics.

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional ...

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...

Susan Monarez told Senators at a hearing Wednesday that Robert F. Kennedy Jr. pushed her out for refusing to rubber-stamp ...

The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do ...